about
The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literatureA missense single-nucleotide polymorphism in the sialic acid acetylesterase (SIAE) gene is associated with anti-PIT-1 antibody syndromeAccelerated Telomere Shortening in Acromegaly; IGF-I Induces Telomere Shortening and Cellular Senescence.SIRT1 regulates adaptive response of the growth hormone--insulin-like growth factor-I axis under fasting conditions in liverIGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner.Anti-PIT-1 antibody syndrome; a novel clinical entity leading to hypopituitarism.Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience.A novel thymoma-associated autoimmune disease: Anti-PIT-1 antibody syndrome.Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma.Prevalence of Simple Renal Cysts in Acromegaly.The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study.Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency.D-dimer as a significant marker of deep vein thrombosis in patients with subclinical or overt Cushing's syndrome.Severe hypophosphatemic osteomalacia with Fanconi syndrome, renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis.The quality of life in acromegalic patients with biochemical remission by surgery alone is superior to that in those with pharmaceutical therapy without radiotherapy, using the newly developed Japanese version of the AcroQoL.A diagnostic pitfall in IgG4-related hypophysitis: infiltration of IgG4-positive cells in the pituitary of granulomatosis with polyangiitis.The prevalence of acromegaly in hospitalized patients with type 2 diabetes.Involvement of PIT-1-reactive cytotoxic T lymphocytes in anti-PIT-1 antibody syndrome.Multiple Salivary Cortisol Measurements Are a Useful Tool to Optimize Metyrapone Treatment in Patients with Cushing's Syndromes Treatment: Case Presentations.Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects.A Novel Clinical Entity of Autoimmune Endocrinopathy: Anti-PIT-1 Antibody Syndrome.The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients.Two Cases of Atezolizumab-Induced Hypophysitis.Autoimmune Pituitary Disease: New Concepts With Clinical ImplicationsIsolated adrenocorticotropic hormone deficiency as a form of paraneoplastic syndromePathogenesis of Anti-PIT-1 Antibody Syndrome: PIT-1 Presentation by HLA Class I on Anterior Pituitary CellsIgG4-related hypophysitis in patients with autoimmune pancreatitisCardiac myxoma caused by fumarate hydratase gene deletion in patient with cortisol-secreting adrenocortical adenomaCongenital pituitary hypoplasia model demonstrates hypothalamic OTX2 regulation of pituitary progenitor cellsAcromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1OR24-1 Structure-Function Analysis of Human OTX2 Variants Defines Required Region of C-Terminus for Pituitary, Eye, and Craniofacial Development[A Novel Clinical Entity "Anti-PIT-1 Antibody Syndrome"--Autoimmunity against a Transcription Factor]
P50
Q26866028-D39747CD-DFD9-42E3-A6DB-DB171237C5CDQ28238523-D6784709-90B1-46DE-ADD1-D3C27C8A90EBQ36136921-FF2B0574-40ED-453F-BE5E-5922A8B70857Q37173234-C9D18460-C062-4D04-870A-8D3AE020BB0FQ37323927-901588D7-5892-4761-92EC-7A75BE9C731BQ38472729-E0959FB6-4F91-4A7A-A2D7-120E6D5CA1A7Q38765930-9C89978D-3E72-4255-8A8C-86662AEE3731Q38952669-B34DE3B9-469A-4D4F-A013-3DDF738E74AFQ39515620-87F689BF-6084-4740-BC57-29F5662792DBQ40668986-5C1A92D5-378A-4FF8-A25E-4A6EE1DD9178Q45199667-93BE5118-70FF-439C-B764-E62715C9A9E9Q45800160-67222CEF-F757-48F5-A669-61ACE23AEECDQ45804015-E2086F9D-51A2-48C8-A951-EF5FB90CBB76Q46104376-66C9FDF7-4288-4ED6-BF12-D44B0CC9F3BEQ48021997-3BDE8A7C-4252-41E6-908C-596A077328D7Q48256152-718AA9FC-F165-4DAC-96F2-736AD74D5E56Q48496269-EA674DA7-F701-4CD0-8955-7DE43A3879BDQ48711303-A5A2C953-730D-40B9-9AD0-FB1EC0EA5A28Q49173327-0C8021CA-CC21-46E4-8A6D-48582FB14001Q50207445-3FFC9242-CBB4-4768-B526-C6876C72F85EQ51118583-10BFE7CF-C938-4B17-930A-83CC06B3FF65Q51286176-17AF122E-DBAC-49B5-8855-D57263F27F04Q52735144-F66FDE49-6A77-4789-AC67-49E9D0A63AD8Q90075096-1F8E9E31-CF7B-4335-B37D-014763FE615FQ90215893-50F68AA9-7DC7-4B8B-ADC7-13144B7E2FABQ90760565-8E365926-D05B-4657-85E4-2AA7ECE0AFBFQ90874637-1BC02F61-03E7-4CBC-8A78-D3482959F0CEQ91584530-379464F2-66BC-4690-AA7E-BC0819D417C9Q92039578-9288D6E4-9669-4240-B4E0-A7C52B2D5A5CQ92690138-B81B5904-FA67-4E3C-A387-47157B78730CQ94432230-0EB56FC0-2F1F-4962-AFA2-8F0CEEA46EDCQ95474061-B704AA81-75B8-4F9F-9FF6-403C1F0D4F00
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hironori Bando
@ast
Hironori Bando
@en
Hironori Bando
@es
Hironori Bando
@nl
type
label
Hironori Bando
@ast
Hironori Bando
@en
Hironori Bando
@es
Hironori Bando
@nl
prefLabel
Hironori Bando
@ast
Hironori Bando
@en
Hironori Bando
@es
Hironori Bando
@nl
P106
P31
P496
0000-0002-7421-2714